Drugs / Revelise
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07146360 | May 2014 → Nov 2017 | myocardial infarction | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Revelise | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07146360 ↗ |
| Modality | Protein / enzyme biologic | “Revelise®, lyophilizate for solution for infusion, 50 mg, is the proposed biosimilar recombinant human tissue plasminogen activator developed by GENERIUM JSC (Russia).” NCT07146360 ↗ |